MTA Application Form

Program Details
Applicant Information
Applicant Name

First NameLast Name
Applicant Email
example@example.com
Applicant Institution
Applicant Position
Please specify your position
Principal Investigator (PI) Information
PI Name

First NameLast Name
PI Email
example@example.com
Technology Transfer Office (TTO) Contact
TTO Contact Name

First NameLast Name
TTO Contact Email
example@example.com
Research / Development Information
Number of Indications / Programs
Number of Indications / Programs
- Disease Indication (1)
- Capsids Used (1)
  e.g., AAV9, AAV PHP.eB, engineered variants.
- Development Stage (1)
  Include high level overview of partial or completed in vitro and/or in vivo studies and payload design status.
- Development Plan (1)
  In a high level summary, describe intended research plan utilizing TfR1 CapX.
- Next Anticipated Regulatory Meeting Type (1)
- Please Specify The Meeting Type (1)
- Meeting Month (1)
- Meeting Year (1)
- Disease Indication (2)
- Capsids Used (2)
  e.g., AAV9, AAV PHP.eB, engineered variants.
- Development Stage (2)
  Include high level overview of partial or completed in vitro and/or in vivo studies and payload design status.
- Development Plan (2)
  In a high level summary, describe intended research plan utilizing TfR1 CapX.
- Next Anticipated Regulatory Meeting Type (2)
- Please Specify The Meeting Type (2)
- Meeting Month (2)
- Meeting Year (2)
- Disease Indication (3)
- Capsids Used (3)
  e.g., AAV9, AAV PHP.eB, engineered variants.
- Development Stage (3)
  Include high level overview of partial or completed in vitro and/or in vivo studies and payload design status.
- Development Plan (3)
  In a high level summary, describe intended research plan utilizing TfR1 CapX.
- Next Anticipated Regulatory Meeting Type (3)
- Please Specify The Meeting Type (3)
- Meeting Month (3)
- Meeting Year (3)
- Disease Indication (4)
- Capsids Used (4)
  e.g., AAV9, AAV PHP.eB, engineered variants.
- Development Stage (4)
  Include high level overview of partial or completed in vitro and/or in vivo studies and payload design status.
- Development Plan (4)
  In a high level summary, describe intended research plan utilizing TfR1 CapX.
- Next Anticipated Regulatory Meeting Type (4)
- Please Specify The Meeting Type (4)
- Meeting Month (4)
- Meeting Year (4)
- Disease Indication (5)
- Capsids Used (5)
  e.g., AAV9, AAV PHP.eB, engineered variants.
- Development Stage (5)
  Include high level overview of partial or completed in vitro and/or in vivo studies and payload design status.
- Development Plan (5)
  In a high level summary, describe intended research plan utilizing TfR1 CapX.
- Next Anticipated Regulatory Meeting Type (5)
- Please Specify The Meeting Type (5)
- Meeting Month (5)
- Meeting Year (5)
- Should be Empty:

Program Details

Applicant Information

Principal Investigator (PI) Information

Technology Transfer Office (TTO) Contact

Research / Development Information